Dual Chamber Versus Single Chamber Cardiac Pacing in People 80 Years of Age and Older
NCT ID: NCT00116987
Last Updated: 2015-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
800 participants
INTERVENTIONAL
2003-08-31
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We wish to determine whether dual chamber or single chamber pacing is associated with a reduction in emergency room visits or hospitalizations for cardiovascular causes (e.g., congestive heart failure (CHF), atrial fibrillation (AF)) resulting in improved quality of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System
NCT01614652
Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation
NCT03503851
Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure
NCT01128816
Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS
NCT04548128
Pacemaker Implantation Following Transcatheter Tricuspid Valve Replacement
NCT06814574
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators wish to determine the optimal pacing mode for this patient population that would enable optimal management of cardiovascular problems, resulting in improved quality of life and minimizing use of health care facilities.
Patients recruited to the study will be randomized to either DDDR or VVIR pacing, and followed in the clinic every 6 months for the 3 years of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
Dual chamber cardiac pacemaker
Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
2
Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
Single chamber cardiac pacemaker
Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dual chamber cardiac pacemaker
Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
Single chamber cardiac pacemaker
Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptomatic bradycardia
Exclusion Criteria
* Previous pacemaker implant
* Life expectancy less than 1 year
* Geographic isolation
* Unable to give informed consent
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Calgary Health Trust
OTHER
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Anne M. Gillis
Professor of Medicine, University of Calgary
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne M Gillis, MD
Role: PRINCIPAL_INVESTIGATOR
Director of Pacing and Electrophysiology, Professor of Medicine, University of Calgary
Derek V Exner, MD, MPH
Role: STUDY_DIRECTOR
University of Calgary
D. George Wyse, MD, PhD
Role: STUDY_DIRECTOR
University of Calgary
L. Brent Mitchell, MD
Role: STUDY_DIRECTOR
University of Calgary
Robert S Sheldon, MD, Ph D
Role: STUDY_DIRECTOR
University of Calgary
John M Rothschild, MD
Role: STUDY_DIRECTOR
University of Calgary
Henry J Duff, MD
Role: STUDY_DIRECTOR
University of Calgary
John Burgess, MD
Role: STUDY_DIRECTOR
University of Calgary
Alexander Bayes, MD
Role: STUDY_DIRECTOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.